ZAVZPRET Drug Patent Profile
✉ Email this page to a colleague
When do Zavzpret patents expire, and when can generic versions of Zavzpret launch?
Zavzpret is a drug marketed by Pfizer and is included in one NDA. There are two patents protecting this drug.
This drug has seventy-one patent family members in thirty-five countries.
The generic ingredient in ZAVZPRET is zavegepant hydrochloride. Two suppliers are listed for this compound. Additional details are available on the zavegepant hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Zavzpret
Zavzpret will be eligible for patent challenges on March 9, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 9, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZAVZPRET?
- What are the global sales for ZAVZPRET?
- What is Average Wholesale Price for ZAVZPRET?
Summary for ZAVZPRET
| International Patents: | 71 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 21 |
| Drug Prices: | Drug price information for ZAVZPRET |
| What excipients (inactive ingredients) are in ZAVZPRET? | ZAVZPRET excipients list |
| DailyMed Link: | ZAVZPRET at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZAVZPRET
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ZAVZPRET
| Drug Class | Calcitonin Gene-related Peptide Receptor Antagonist |
| Mechanism of Action | Calcitonin Gene-related Peptide Receptor Antagonists |
US Patents and Regulatory Information for ZAVZPRET
ZAVZPRET is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZAVZPRET is ⤷ Sign Up.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ZAVZPRET
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
FDA Regulatory Exclusivity protecting ZAVZPRET
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZAVZPRET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | ZAVZPRET | zavegepant hydrochloride | SPRAY, METERED;NASAL | 216386-001 | Mar 9, 2023 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZAVZPRET
See the table below for patents covering ZAVZPRET around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
